# A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit

Source: https://onco.cc/trials/nct06365853/  
OnCo record `nct06365853` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mirvetuximab soravtansine in ovarian cancer, run by AbbVie, active and no longer recruiting.

## Summary

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression is a phase 2 interventional study registered as NCT06365853 by AbbVie, with 108 participants enrolled, started 2024-07-29 and due to reach its primary completion in 2027-02. Interventions recorded: Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops. Conditions listed: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06365853
- Phase: 2
- Setting: A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
- Sponsor: AbbVie
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT06365853: https://clinicaltrials.gov/study/NCT06365853

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06365853.json